Exonics Therapeutics, Inc.

Many biopharma companies have targeted KRAS mutations in the fight against cancer, most with little success, but bicoastal US biotech Affini-T Therapeutics Inc. thinks it will succeed in treating soli

Vertex Pharmaceuticals Incorporated increased its wager on a gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia on 20 April, paying CRISPR Therapeutics AG $900m

Analysts have been stunned by the launch of Vertex Pharmaceuticals Inc. 's Trikafta, with the first triple combination therapy for cystic fibrosis recording a whopping $420m in revenues iust nine wee

In 2019, attention-grabbing headlines such as Roche ’s acquisition of Spark Therapeutics Inc. for $4.8bn, Biogen Inc. ’s $877m play for Nightstar Therapeutics PLC , and Vertex Pharmaceuticals In